CBFB and essential thrombocythemia: In metastatic ET patients, CBFB-mutated tumors (n = 80) demonstrated significantly longer TTP (hazard ratio [HR], 0.44; 95% CI, 0.29-0.67; P = .0002, FDR q = .010) with no chemotherapy benefit (HR, 1.16; P = .65).